Gene expression

**FuSe: a tool to move RNA-Seq analyses from chromosomal/gene loci to functional grouping of mRNA transcripts**

Rajinder Gupta 1, Yannick Schroeders1, Marcha Verheijen1, Adrian Roth2, Jos Kleinjans1 and Florian Caiment1,*

1Department of Toxicogenomics, School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, 6229ER, The Netherlands and 2Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, CH-4070, Switzerland

*To whom correspondence should be addressed.

Associate Editor: Yann Ponty

Received on January 25, 2020; revised on July 13, 2020; editorial decision on August 11, 2020; accepted on August 13, 2020

**Abstract**

**Summary:** Typical RNA sequencing (RNA-Seq) analyses are performed either at the gene level by summing all reads from the same locus, assuming that all transcripts from a gene make a protein or at the transcript level, assuming that each transcript displays unique function. However, these assumptions are flawed, as a gene can code for different types of transcripts and different transcripts are capable of synthesizing similar, different or no protein. As a consequence, functional changes are not well illustrated by either gene or transcript analyses. We propose to improve RNA-Seq analyses by grouping the transcripts based on their similar functions. We developed FuSe to predict functional similarities using the primary and secondary structure of proteins. To estimate the likelihood of proteins with similar functions, FuSe computes two confidence scores: knowledge (KS) and discovery (DS) for protein pairs. Overlapping protein pairs exhibiting high confidence are grouped to form ‘similar function protein groups’ and expression is calculated for each functional group. The impact of using FuSe is demonstrated on in vitro cells exposed to paracetamol, which highlight genes responsible for cell adhesion and glycogen regulation which were earlier shown to be not differentially expressed with traditional analysis methods.

**Availability and implementation:** The source code is available at https://github.com/rajinder4489/FuSe. Data for APAP exposure are available in the BioStudies database (http://www.ebi.ac.uk/biostudies) under accession numbers S-HECA143, S-HECA158 and S-HECA139.

**Contact:** florian.caiment@maastrichtuniversity.nl

**Supplementary information:** Supplementary data are available at *Bioinformatics* online.

1 **Introduction**

With the evolution of RNA sequencing (RNA-Seq), an immense amount of high-quality transcriptomics data has been generated; identifying and quantifying each gene transcript/isoform with high precision. Transcriptomics data are often studied to identify the changes in gene or transcript expression between different conditions and treatments. The ones exhibiting the highest perturbation at the lowest statistical error are then mapped to pathways and ontologies to illuminate the functional consequences of the alteration. However, the typical data analysis pipelines to assess gene expression from RNA-Seq dataset are not perfect. The expression level of a given gene is usually obtained by the summation of expression (read count) of all the different spliced variants (isoforms/transcripts) mapping the gene locus. These spliced variants are identified using the sequence identity to the genome and chromosomal locus. These isoforms can be protein coding (same or different proteins), non-coding and non-sense mediated decay. Considering the level of expression of a gene as the summation of all reads from these different types of isoforms is misrepresentative as it considers all of them as coding for the same protein.

Alternatively, analyzing RNA-Seq data at the level of isoform can also be performed by keeping an individual read count for every single transcript. Keeping each isoform separated would assume that there are no functional overlaps between different transcripts. Currently, most of the tools available to quantify RNA-Seq data like RSEM (Li and Dewey, 2011), StringTie (Pertea et al., 2015), Sailfish (Patro
Rather than defining gene expression that groups together the transcripts from the same chromosomal locus, we developed FuSe (functional grouping of transcripts for RNA-Seq analyses) with an aim to group protein coding transcripts based on the predicted similarity of their protein function. For this, we used the available primary structure of proteins and predicted the secondary, super-secondary structures, and protein families from it. For establishing the similarity from the protein primary sequence, BLAST+ (Camacho et al., 2009) was used to identify sequence identity, coverage and gaps in the alignment. While sequence identity establishes the similarity between the proteins, the coverage provides information if the two sequences match globally or locally. The gaps further help in checking the presence of any insertions or deletions and hence provide information about the alignment continuity. Interpro is an ensemble of 14 different tools developed using state-of-the-art algorithms and knowledgebase to find and predict the domains, motifs and protein families (Mitchell et al., 2018).

On the foundations of this information, two types of confidence scores, knowledge (KS) and discovery (DS), are calculated for all protein pairs. KS is stringent and predicts highly similar protein pairs whereas DS is lenient and predicts the proteins with local similarity as well. Based on the confidence score, ‘similar function protein groups’ (SFPGs) are formed from the overlapping protein pairs and are used for recalculating the RNA-Seq expression. To assess the approach and illustrate the changes in functional inferences between the chromosomal locus and function-based grouping, mRNA data from hepatic cell models exposed to acetaminophen (APAP or paracetamol) were used.

### 2 Materials and methods

All the protein coding transcripts for human were downloaded from Ensembl (Homo_sapiens.GRCh38.pep.all.fa) (Frankish et al., 2018). For the workflow of FuSe, refer Supplementary Figure S1.

#### 2.1 Data preparation

To find the similarity between the protein sequences, BLAST+ (v.2.8.0) was used and data was generated in tabular format 6 of BLAST+. Then, to find and predict the presence of structural and functional domains in the proteins, Interpro (v.5.31–70.0) was used. The data were obtained in the ‘.csv’ format.

The output from Interpro was a list of functional and structural domains obtained from various tools embedded in Interpro. Using in-house developed scripts, for each protein, these domains are first ordered based on their position on the amino acid sequence per tool. These ordered domains were then compared for similarities between the protein pairs. The similarity between the ordered domains was labeled for each tool per protein pair as STONM (same type, order and number of motifs), STNM (same type and number of motifs), STM (same type of motifs) and NM (no match) (Supplementary Fig. S2). STONM defines the highest level of similarity. Another term, NP (not present) was assigned to cases where there was no prediction by an Interpro tool for at least one of the proteins in the given protein pair. Each protein pair will have one term (STONM, STNM, STM, NM or NP) for each of the 14 tools and, from this information, a protein–protein domain profile per tool is obtained.

#### 2.2 Protein pair confidence scores

From the BLAST+ and protein–protein domain profile comparison, the protein pair confidence scores were calculated using a scoring scheme (Supplementary Methods). Two types of confidence scores, DS and KS, were calculated; succinct and expanded equations are as follows:

**Succinct equations:**

\[
DS = \frac{(AIS + ACS + AGS) \times 100}{\text{Max AIS}}
\]

\[
KS = \frac{AIS + ACS + AGS + \text{ITCSs} \times 100}{\text{Max ITCS}}
\]

where AIS, alignment identity score; ACS, alignment coverage score; AGS, alignment gap score; ITCS, sum of Interpro tools’ comparison score.
Transcripts belonging to different SFPGs. A lower CSC would result in the formation of SFPG with false positives. It is important to establish here that a given transcript can be similar in function, a confidence score cutoff (CSC) was used with a default value of KS = 95. The CSC can be any positive integer ≤ 100. A lower CSC would result in the formation of SFPG with false positives. It is important to establish here that a given transcript can be a member of one or more SFPGs, as it can have a certain sufficient amount of similarity (above the assigned DS or KS threshold) with transcripts belonging to different SFPGs.

2.3 Similar function protein groups
Confidence scores were calculated from all possible protein pairs as described in the previous step. To identify the proteins which are similar in function, a confidence score cutoff (CSC) was used with a default value of KS ≥ 95. The CSC can be any positive integer ≤ 100. A lower CSC would result in the formation of SFPG with false positives. It is important to establish here that a given transcript can be a member of one or more SFPGs, as it can have a certain sufficient amount of similarity (above the assigned DS or KS threshold) with transcripts belonging to different SFPGs.

2.4 Calculating SFPG expression
This step is divided into two parts: first the normalization of the raw reads followed by the calculation of the SFPG expression. For the normalization, the raw read counts of the transcripts and their effective length were used as calculated by RSEM.

\[
\text{Expanded equations:}
\]

\[
\text{Discovery score (DS)} = \left( \sum_{j=1}^{2} \left( \frac{\% \text{ Identity} \times \text{Identity score}}{100} + \frac{\text{seq length} \times \text{Coverage score}}{100 \times \text{alignment length} \times \text{alignment length}} + \frac{\text{Number of gaps} \times \text{Gap score}}{100} \right) \right) \times \frac{100}{\text{Identity score}}
\]

\[
\text{Knowledge score (KS)} = \left( \sum_{j=1}^{14} \left( \frac{\% \text{ Identity} \times \text{Identity score}}{100} + \frac{\text{seq length} \times \text{Coverage score}}{100 \times \text{alignment length} \times \text{alignment length}} + \frac{\text{Number of gaps} \times \text{Gap score}}{100} \right) \right) \times \sum_{j=1}^{14} \left\{ \begin{array}{ll}
\text{if comparison} = \text{STONM, STNM, STM, NM or NP,} & \text{Max Interpro tool score} \\
\text{else if comparison} = \text{NP,} & \text{skip}
\end{array} \right.
\]

The DS relies only on the sequence similarity attributes obtained from sequence alignment such as identity, coverage and gaps. While identity and coverage score have a positive value, they illustrate the similarity between the protein pair, the Gap score has a negative value and demonstrates their dissimilarity. The score obtained is then normalized to 100 using the maximum possible alignment identity score. In the case of KS, the final score is a result of sequence similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similarity given as STONM, STNM, STM, NM or NP. To avoid penalizing protein similarity attributes and ordered secondary structure similar...
used for further analyses. For using the future updates to Ensembl protein sequences, BLAST+ or/and Interpro, create a new bi.do using the steps mentioned on FuSe’s Github repository. The data object provided is generated using the protein coding transcripts only; however, if the user intends, other types of transcripts can also be used for instance non-sense mediated decay, polymorphic pseudogene, non-stop decay, etc. refer Readme for FuSe’s repository on GitHub.

2.5 Assessment of FuSe

To illustrate the significance of using FuSe, we used a RNA-Seq dataset obtained from a three-dimensional human hepatic cell model (Primary Human Hepatocytes + Kuepfer cells Spheroids from InSpherö®) exposed to APAP. Ribo-depleted libraries were generated from these cell models and sequenced on an Illumina HiSeq2000 (Supplementary Methods) at an average of 41.3 million reads per sample in 100 bp paired-end (Supplementary Fig. S6).

There were four sets of samples: control untreated (ConUNTR), control exposed to DMSO (ConDMSO), exposed to therapeutic dose (Ther) and exposed to toxic dose (Tox). ConUNTR and Ther had five time points: 0, 2, 8, 24 and 72 h, and ConDMSO and Tox had four time points: 2, 8, 24 and 72 h. Each time point had three replicates, totaling 54 samples. The therapeutic dose was calculated based on physiologically based pharmacokinetic modeling using human kinetic data, and the toxic dose was obtained from IC20 (Kuepfer et al., 2018). Data are available in the BioStudies database (http://www.ebi.ac.uk/biostudies) under accession numbers S-HECA143, S-HECA158, S-HECA139 (APAP link for reviewers: https://www.ebi.ac.uk/biostudies/studies/S-HECA143?key=31dad9db-da50-47a6-b16e-e9108e935f43). Reads above Q30 for ConUNTR, ConDMSO, Ther and Tox samples constituted 85.19, 88.43, 94.5 and 94.2% of all reads, respectively. FPKM for transcripts was calculated using RSEM and from its expression for SFPGs was calculated using FuSe. Principal component analysis (PCA) and hierarchical clustering were done for top 500 expressed transcripts using R packages: pcomp() and hclust(), respectively, for isoform FPKM and recalculated SFPG expression to compare them. Then differentially expressed transcripts (DETs) were evaluated using Anova package in R for all dose versus control samples: ConUNTR versus Ther, ConUNTR versus Tox, ConDMSO versus Ther, ConDMSO versus Tox and Ther versus Tox samples. Significant cutoff was set to P-value < 0.01 and |log2FC| > 1. Changes in the DETs between the original FPKM and recalculated expression were also established.

3 Results

In order to move from a loci-based transcriptomics analysis to a function-based analysis, we first need to identify all protein coding transcripts from the human genome. For this, a total of ~107k proteins were retrieved from Ensembl, of which 719 proteins were discarded which originated from transcripts annotated as non-sense mediated decay, polymorphic pseudogene, T-cell receptor genes and immunoglobulin genes. From the remaining transcripts, protein pairs were formed and two confidence scores (KS and DS) were calculated to estimate the likelihood of similar functions. Taken individually, both scores are used to make the protein pairs and a CSC (here used: 85, 90 and 95 for both KS and DS) is introduced to discard the protein pairs with low similarity. While both DS and KS show a steep increase in the number of pairs with the lowering of CSC, a steep increase for DS can be seen (Fig. 1A). The protein pairs can be divided into four categories depending on the origin of the transcripts, namely, same gene, same gene family, different gene or undefined (Fig. 1B). A considerable amount of protein pairs originated from the same or different gene families at KS and DS ≥ 95.

Moreover, a surge can be witnessed with decreasing CSC. With the protein pairs at different CSCs, SFPGs are formed and a similar trend of increase in the group size (Fig. 1C), the sum of group sizes per CSC and maximum group size for an SFPG (Supplementary Fig. S5A) with decreasing CSC can be seen. The median for the group size per CSC remains low (Supplementary Fig. S5B), implying that most groups are small. The increase in group size for the biggest group per CSC was also apparent (Supplementary Fig. S5C). For KS and DS at ≥95, the largest group size was 84 and 111 which rose to 216 and 229 at ≥85, respectively.

To evaluate the impact of SFPG on biological interpretation, we applied FuSe on an in vitro transcriptomics dataset obtained from a hepatic cell model exposed to different doses (therapeutic and toxic) of APAP for variable time duration and corresponding controls (untreated and DMSO). The dataset was analyzed by locus-based and our function-based method. For this, SFPGs at KS ≥ 95 were taken to particularly consider the highly similar protein pairs predicted using maximum available knowledge. The expression for the SFPGs was calculated from the normalized FPKM using both methods, namely, ‘ED’ and ‘GD’ (cf. Section 2.4). Differences in the recalculated expression from ED and GD are discussed in Supplementary Results and Fig. S7. The primary analyses shown in this paper makes use of the recalculated expression obtained using the ‘GD’ method to give a higher importance to bigger SFPGs, implying that important biological processes are conserved. The term ‘recalculated expression’ from here on would mean the recalculated expression from ‘GD’. The normalized FPKM and recalculated expression (GD) from FuSe were then compared. PCA bi-plots and clustering (Fig. 2 and Supplementary Fig. S8A-E) were done to show that FuSe preserves the inter-sample variation and global profile of the samples. The highest source of variation between the samples was dose and it was conserved.

Furthermore, DETs were calculated for the FPKM and recalculated expression obtained using FuSe, individually for all control versus dose samples. Lesser number of DETs were observed after applying FuSe (Fig. 3 and Supplementary Table S1). We also observed many transcripts that were significantly differentially
expressed in FPKM but non-significant after using FuSe and vice versa (Fig. 3, blue bars and green bars, respectively). With loci-based analyses, the differences were computed at the transcript level while using FuSe the changes at the functional level were captured. Using FuSe, the expression levels were correctly quantified as a result of the expression of other similar function proteins. In the case of ConUNTR versus Tox and ConDMSO versus Tox, this is illustrated by protein coding transcripts from many genes responsible in cell adhesion and tight junction such as PKK2-201 (Plakophilin-2), CHCHD3-203 (MICOS complex subunit), CHCHD3-201 (MICOS complex subunit MIC19), IMMT-205 (MICOS complex subunit MIC60), AGRN-201 (Agrin), WDR1-205 (WD repeat-containing protein 1), CTNNA1-243 (Catenin alpha-1), ZBTB33-202 (Transcriptional regulator Kaiso), ASPH-201 and ASPH-207 (Aspartyl/asparaginyl beta-hydroxylase). All these transcripts, not considered differentially expressed by the standard analysis method, were found significantly affected by a toxic dose of APAP after applying FuSe.

More importantly, some transcripts displaying a significant regulation (up or down) using the conventional analysis method were found to be significantly regulated in the opposite direction after using FuSe (Fig. 4 and Supplementary Fig. S9). The highest number of switches was seen for ConUNTR versus Ther. A total of 79 unique transcripts changed their direction of regulation (from upregulated to downregulated and vice versa), and 3727 changed from differentially expressed to not differentially expressed (and vice versa) across all comparisons. As an example, PPP1R14B-203 (Protein phosphatase 1 regulatory subunit 14B) was observed (Fig. 5). While for PPP1R14B-203, the change could be seen for ConDMSO versus Ther and ConUNTR versus Tox, for GBE1-205, the switch was witnessed for ConUNTR versus Tox and ConDMSO versus Tox.

FuSe also demonstrated how gene expression-based analyses sometimes lead to incorrect results. As there are multiple different protein coding transcripts for a gene, to compare the expression of the gene to the transcripts, we selected the longest protein coding transcripts for the comparison. Moreover, for the APAP study, there were ~59% genes where the longest protein coding transcript was the highest expressed transcript; making them a suitable candidate for the comparison. The differences between the gene and SFG expression can be illustrated here using two cases, POLR2J2 (RNA polymerase II subunit J2) from ConUNTR versus Ther and UBE2D4 (ubiquitin-conjugating enzyme E2 D4) from ConUNTR versus Tox (Fig. 6). While the gene expression of POLR2J2 is contributed by two transcripts (both protein coding), the expression of SFG (POLR2J2-202) is attributed by four similar protein coding transcripts (KS = 98.02%). The expression of the longest protein coding isoform follows the pattern of the gene expression; however, the SFG expression comprises of expression of 11 transcripts (one retained intron, one processed transcript, seven non-sense mediated decay and two protein coding), the SFG expression of the longest protein coding transcript from the gene (UBE2D4-201) is contributed by 18 similar protein coding transcripts (KS = 96.05%). The longest protein coding transcript follows the pattern of SFG though the magnitude is much higher as illustrated by SFG.

4 Discussion

Biological research aims to find the functional properties and changes in the biological system, which makes us question the very fabric of our current RNA-Seq analyses strategies that focuses on changes in individual genes or transcripts. While the information of each gene or transcript is informative, however, at the system level, contribution by each element should be viewed in terms of functional change. Elevating the analyses of the RNA-Seq to the functional...
level will increase our understanding of the biological systems and their underlying processes. Due to the limitations in quantifying the whole panel of expressed proteins and limited knowledge of protein tertiary and quaternary structure, and functions identifying the proteins having similar functions is challenging. Here, we focused on the primary and secondary structure of the proteins to establish their functional similarity.

The hypothesis that similar primary sequence and secondary structures make the proteins possessing similar functional properties can be challenged at various levels; however, it is an acceptable hypothesis (Gong and Rose, 2005) and holds true for most cases as shown by studies of homologs and paralogs (Jensen, 2001). Protein trees calculated from sequence similarity often have the same topologies as those calculated from structural similarity. While some cases might be overlooked for instance a point mutation, which can result in a different conformation of the protein, they will not have a significant influence on the sequence alignment and secondary structure prediction (if not present in the prediction region). Moreover, other external factors such as molecular crowding or macromolecular environment cannot be accounted for while taking into account only the primary and secondary structures.

Even though primary and secondary structures exhibit some limitations to predict similar proteins, they allow us to group similar function proteins and form SFPGs. FuSe uses amino acid sequences of the proteins thus eliminating all non-coding transcripts from the analyses. While many non-coding transcripts have been associated with a specific function, not enough data are available at this stage to allow a generic in silico grouping of non-coding RNA sharing a similar biological function. Moreover, the transcripts annotated as non-sense mediated decay, polymorphic pseudogene, T-cell receptor genes and immunoglobulin genes were removed from the formation of SFPGs. Non-sense mediated decay transcripts were removed because they are destined to be decayed before entering the ribosomal machinery for protein synthesis. In the case of the polymorphic pseudogenes, they have lost their functional properties over evolution and may result in non-functional proteins. T-cell receptor and immunoglobulin genes are very selective for their targets and even if they share high similarity among them, they have different affinities for their targets and hence cannot be considered as a similar functional entity. Even though these transcript types are removed from the creation of SFPGs, they are retained with their original expression in the recalculated expression.

The SFPGs are, hence, formed of only the protein coding transcripts. The similarity of the proteins is established using the two score types: DS and KS. DS makes an over-prediction because it relies only on the amino acid sequence, providing little information on the final structure and hence function(s) of the protein. KS is more conservative and takes into account other available knowledge to establish similarity. The lenient nature of DS makes it a powerful tool to find novel protein pairs whereas KS, being stringent, under-estimates and limits the ballooning of the groups by keeping only highly similar proteins together. DS can be used in finding the local similarities in proteins and thus allows the discovery of a subset of common functions between two proteins whereas KS thrives for global functional similarity.

It is worth noting here that an SFPG is made for each protein coding transcript that has other similar protein coding transcripts, in order to preserve the specialized protein functions. It resulted in redundancy, as some transcripts can be a member of multiple SFPGs and these SFPGs might then be semi- or fully overlapping. If such SFPGs were merged, it would result in the formation of false-positive SFPGs (decreased specificity) and the consecutive loss of some specialized protein functions. As some transcripts were shared between many groups, for the calculation of expression of the SFPGs, two methods are made available. First, equally dividing the expression of member transcripts between all the overlapping SFPGs and the other where the expression is divided between the SFPGs based on the group size of each SFPG, giving higher expression to bigger groups. While the first method is conservative giving equal importance to all SFPGs, the second is biased toward the bigger SFPGs, establishing that the important functions are more preserved. The quantification of the SFPG expression using FuSe requires in-sample normalized data because it needs to compare the transcripts within the sample for its calculation. Moreover, the expression should also be normalized across samples to compare it across samples. We calculated the FPKM from the normalized expression which was obtained using DESeq2. As a consequence, SFPGs are advised to be studied in relative analysis comparing a given SFPG between two biological conditions rather than for evaluating their absolute expression level among the different SFPGs.

The results from the comparison of FPKM and expression of SFPGs using FuSe from the hepatic cell model established that the changes in the expression of the transcripts acquired using FuSe do not change the overall look of the samples, though the changes at the level of SFPGs were apparent and pointed toward different functional inferences. For instance, genes responsible for cell adhesion and tight junctions were initially shown to be not differentially expressed. However, the application of FuSe completely changes the biological interpretation of this signal, confirming the documented APAP effects (Blair et al., 1989; Gamal et al., 2017).

There were also cases of transcripts that were differentially expressed in the opposite direction after correction using FuSe, e.g. PPP1R14B-203 (ConDM0 versus Ther) and GBE1-205 (ConUNTR versus Tox) (Fig. 4). The correction by FuSe reversed the direction of perturbation and hence completely changed the inferences drawn from the results. PPP1R14B is responsible for inhibition of PP1ICA, which is involved in different processes such as cell division, regulation of glycogen metabolism, muscle contractility and protein synthesis via dephosphorylation (Ni et al., 2007; Song et al., 2015). For the therapeutic dose of APAP, the upregulation of PPP1R14B as shown by FPKM-based differential expression would imply all these processes to be inhibited. Similarly, GBE1 was shown to be upregulated under APAP toxic dose, implying that the glycogen accumulation in the liver has increased. However, APAP is known to induce glycogen depletion and is considered as one of the early biomarkers of acetaminophen-induced hepatotoxicity (Gautam et al., 2012). Using FuSe, the GBE1 function is shown to be downregulated. The use of SFPGs also demonstrated why studying expression to attribute differentially expressed genes can be misleading, as in the case of UBE2D4 (gene expression: downregulated; SFPG expression: upregulated) and POLR2J2 (gene expression: upregulated).
expression: upregulated; SFP expression: downregulated. UBE2D4 is involved in ubiquitination (David et al., 2010) and POLR2J2 is an important component of RNA polymerase II. The downregulation of POLR2J2 would result in a decrease in transcription while the upregulation of UBE2D4 implies more ubiquitination leading to increased protein degradation. This suggests a decrease in protein levels in the cell, and hence, the disruption of cell processes, which is consistent with the knowledge on APAP overdose.

FuSe showed how moving from loci-based to function-based analyses changed the inferences derived from the RNA-Seq data. It illustrated functional changes that could not be captured using the conventional RNA-data analyses. Moreover, FuSe is forward compatible and new data that will be available in the future for transcript-protein sequences and secondary structures can be integrated into the analysis by following the steps mentioned for ‘creating your own BLAST Interpro data object’ under Section 2. In the future, we will look to fine-tune the calculation of CSC using genes have to be studied further to understand the processes and signals responsible for guiding different genes to make similar proteins.

## Acknowledgements

A special thanks to Dr. Terezinha de Souza, Juan Ochoteco Asensio, Tim Kuipers and Nhan Nguyen for their help in testing FuSe. The authors would also like to extend their gratitude to Dr. Tuan van de Beucken for his help in understanding different types of transcripts.

## Funding

This work was supported by the EU-ToxRisk project (An Integrated European ‘Flagship’ Program Driving Mechanism-Based Toxicity Testing and Risk Assessment for the 21st Century) and funded by the European Commission under the Horizon 2020 Program [grant agreement number 681002]. Data were taken from the European Union Seventh Framework Programme HeCaToS (Hepatic and Cardiac Toxicity Systems modelling) [FP7/2007-2013].

Conflict of Interest: None declared.

## References

Abascal, F. et al. (2010) TranslatorX: multiple alignment of nucleotide sequences guided by amino acid translations. *Nucleic Acids Res.*, 38, W7–W13.

Anders, S. et al. (2015) HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics*, 31, 166–169.

Artimo, P. et al. (2012) ExpPaSy: SIB bioinformatics resource portal. *Nucleic Acids Res.*, 40, W597–W603.

Berman, H. M. et al. (2000) The Protein Data Bank. *Nucleic Acids Res.*, 28, 235–242.

Blair, J. B. et al. (1989) Morphological changes in trout hepatocytes exposed to acetaminophen. *Mar. Environ. Res.*, 28, 357–361.

Bray, N. L. et al. (2016) Near-optimal probabilistic RNA-seq quantification. *Nat. Biotechnol.*, 34, 525–527.

Camacho, C. et al. (2009) BLAST+: architecture and applications. *BMC Bioinform.*, 10, 421.

Conway, J. R. et al. (2017) UpSetR: an R package for the visualization of intersecting sets and their properties. *Bioinformatics*, 33, 2938–2940.

David, Y. et al. (2010) The EZ ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines. *J. Biol. Chem.*, 285, 8593–8604.

Frankish, A. et al. (2018) Ensembl 2018. *Nucleic Acids Res.*, 46, D754–D761.

Gamat, W. et al. (2017) Low-dose acetaminophen induces early disruption of cell-cell tight junctions in human hepatic cells and mouse liver. *Sci. Rep.*, 7, 37541–37541.

Gautam, R. et al. (2012) Identification of early biomarkers during acetaminophen-induced hepatotoxicity by Fourier transform infrared microspectroscopy. *PLoS One*, 7, e45521.

Gong, H. and Rose, G. D. (2005) Does secondary structure determine tertiary structure in proteins? *Proteins*, 61, 338–343.

Hegde, A. N. (2009) Ubiquitin-proteasome system and plasticity. In: Squire, L. R. (ed.) *Encyclopedia of Neuroscience*, Academic Press, Oxford, pp. 1–9.

Jensen, R. A. (2001) Orthologs and paralogs—we need to get it right. *Genome Biol.*, 2, interactions1002.1–interactions1002.3.

Koussounadis, A. et al. (2015) Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. *Sci. Rep.*, 5, 10775–10775.

Kuepfer, L. et al. (2018) A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity. *Arch. Toxicol.*, 92, 533–535.

Li, B. and Dewey, C. N. (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinform.*, 12, 323.

Liu, Y. et al. (2016) On the dependency of cellular protein levels on mRNA abundance. *Cell*, 165, 535–550.

Marin˜o-Ramirez, L. et al. (2005) Histone structure and nucleosome stability. *Exp. Res. Proteomics*, 2, 719–729.

McWilliam, H. et al. (2013) Analysis tool web services from the EMBL-EBI. *Nucleic Acids Res.*, 41, W597–W600.

Mi, J. et al. (2007) Protein phosphatase-1alpha regulates centrosome splitting through Nek2. *Cancer Res.*, 67, 1082–1089.

Mitchell, A. L. et al. (2019) InterPro in 2019: improving coverage, classification and access to protein sequence annotations. *Nucleic Acids Res.*, 47, D351–D360.

Moul, J. et al. (2018) Critical assessment of methods of protein structure prediction (CASP)-Round XII. *Proteins*, 86, 7–15.

Nowak, M. A. et al. (1997) Evolution of genetic redundancy. *Nature*, 388, 167–171.

Pappiredi, N. et al. (2019) A review on quantitative multiplexed proteomics. *ChemBioChem*, 20, 1210–1224.

Patro, R. et al. (2014) Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms. *Nat. Biotechnol.*, 32, 462–464.

Patro, R. et al. (2015) Salmon: accurate, versatile and ultrafast quantification from RNA-seq data using lightweight-alignment. *BioXrix*, 021592. doi: 10.1101/021592.

Pelley, J. W. (2007) 3. Protein structure and function. In: Pelley, J. W. (ed.), *Elsevier’s Integrated Biochemistry*, Mosby, Philadelphia, pp. 19–28.

Perica, M. et al. (2015) StringEye enables improved reconstruction of a transcriptome from RNA-seq reads. *Nat. Biotechnol.*, 33, 290–295.

Song, H. et al. (2015) ATG16L1 phosphorylation is oppositely regulated by CSNK2/casein kinase 2 and PPI/protein phosphatase 1 which determines the fate of cardiomyocytes during hypoxia/reoxygenation. *Autophagy*, 11, 1308–1325.

The UniProt Consortium. (2015) UniProt: a hub for protein information. *Nucleic Acids Res.*, 43, 27.

Trapnell, C. et al. (2013) Differential analysis of gene regulation at transcript resolution with RNA-seq. *Nat Biotechnol.*, 31, 46–53.